Skip to main content
. 2022 Oct 20;8(12):1825–1829. doi: 10.1001/jamaoncol.2022.4733

Figure 2. Serum Atezolizumab Concentration and T-Cell Functions According to Antidrug Antibody (ADA) Status.

Figure 2.

A, Correlations between serum atezolizumab and ADA concentration. B, Comparisons of serum atezolizumab concentrations according to ADA level. C, Ki67-positive proliferating CD8-positive T cells between baseline and C2D1 according to ADA status. D, Interferon-γ and tumor necrosis factor-α from CD8-positive T cells according to ADA status.